ClinicalTrials.gg
CompletedNCT02137772Updated Sep 11, 2019Results posted

Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)

A Phase 3 interventional study of Letermovir and Placebo in Prevention of CMV Infection or Disease, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-11.

Primary conditionnone(registry's first term: Disease)No conditionIs this wrong?Disease describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
570
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study evaluated the efficacy and safety of letermovir (MK-8228) for the prevention of clinically-significant CMV infection in adult, CMV-seropositive recipients of allogeneic hematopoietic stem cell transplant (HSCT). The hypothesis being tested was that MK-8228 is superior to placebo in the prevention of clinically-significant CMV infection through Week 24 post-transplant.

02

Conditions studied

  • Prevention of CMV Infection or Disease

Browse trials for

03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has documented seropositivity for CMV within 1 year before hematopoietic stem cell transplant ()
  • Receiving first allogeneic HSCT (bone marrow, peripheral blood stem cell, or cord blood transplant)
  • Female or male participant who is not of , or, if of reproductive potential, agrees to true abstinence or to use (or have their partner use) 2 acceptable methods of from the time of consent through 90 days after the last dose of study drug
  • Able to read, understand, and complete questionnaires and diaries

Exclusion criteria

Exclusion Criteria:

  • Received a previous HSCT (previous autologous HSCT is acceptable)
  • History of CMV end-organ disease within 6 months before randomization
  • Has evidence of CMV viremia (if tested) at any time from either signing of the Form or the HSCT procedure, whichever is earlier, until the time of randomization.
  • Received the following within 7 days before screening or plans to receive during the study: ganciclovir, valganciclovir, foscarnet, acyclovir, valacyclovir, or famciclovir
  • Received the following within 30 days before screening or plan to receive during the study: cidofovir, CMV hyper-immune globulin, any CMV antiviral agent or biological therapy
  • Has suspected or known to ingredients of MK-8228 (letermovir) formulations
  • Has severe hepatic insufficiency within 5 days before randomization
  • Has end-stage renal impairment
  • Has an uncontrolled infection on the day of randomization
  • Requires mechanical ventilation or is hemodynamically unstable at the time of randomization
  • Has documented positive results for (HIV) antibody, virus (HCV) antibody with detectable HCV ribonucleic acid, or surface antigen (HBsAg) within 90 days before randomization
  • Has active solid tumor with the exception of localized basal cell or squamous cell skin cancer or the condition under treatment (for example, lymphoma)
  • Is pregnant or expecting to conceive, is breastfeeding, or plans to breastfeed from the time of consent through 90 days after the last dose of study drug
  • Is expecting to donate eggs or sperm from the time of consent through 90 days after the last dose of study drug
  • Has participated in a study with an unapproved investigational compound (monoclonal antibodies are excepted) or device within 28 days of the first dose of study drug
  • Has previously participated in a MK-8228 (letermovir) study
  • Has, is, or is planning (during the study) to participate in any study involving administration of a CMV vaccine or another CMV investigational agent
  • Is a user of recreational or illicit drugs or has a recent history (\<=1 year) of drug or alcohol abuse or dependence
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
570 participants (actual)

Study arms

  • Experimental
    Letermovir

    Letermovir oral or intravenous (IV) formulation was administered once daily for up to 14 weeks, beginning up to Day 28 days post-transplant. The dose was 240 mg once daily for participants receiving concomitant cyclosporin A and 480 mg once daily for participants not receiving cyclosporin A. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.

    Drug: Letermovir

  • Placebo comparator
    Placebo

    Placebo oral or IV formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The number of placebo tablets was to mimic that for letermovir administration according to the concomitant cyclosporin A status. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.

    Drug: Placebo

Interventions

  • Letermovir 240 mg / 480 mg tablets, or 240 mg / 480 mg intravenous solution in 250 mL to be infused over 60 minutes.

    Also known as: MK-8228

  • DrugPlacebo

    Placebo tablets, or intravenous solution in 250 mL to be infused over 60 minutes.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Clinically-significant CMV Infection up to Week 24 Post-transplant

    Clinically-significant CMV infection was defined as either one of the following: 1) onset of CMV end-organ disease, or 2) initiation of anti-CMV pre-emptive therapy based on documented CMV viremia and the clinical condition of the participant. The percentage of participants with clinically-significant CMV infection was assessed.

    Time frame: Up to Week 24 post-transplant

Secondary outcomes

  1. Time to Onset of Clinically-significant CMV Infection (Kaplan-Meier Estimate of Percentage of Participants With a Qualifying Event at Week 24 Post-transplant)

    Clinically-significant CMV infection was defined as either one of the following: 1) onset of CMV end-organ disease, or 2) initiation of anti-CMV pre-emptive therapy based on documented CMV viremia and the clinical condition of the participant. Time to onset of clinically-significant CMV infection was defined from the day of transplantation to the day the participant developed clinically-significant CMV infection, and was analyzed by the Kaplan-Meier method. Participants were censored at the last assessment for participants who discontinued or did not develop clinically-significant CMV infection.

    Time frame: Up to Week 24 post-transplant

  2. Percentage of Participants With Clinically-significant CMV Infection up to Week 14 Post-transplant

    Clinically-significant CMV infection was defined as either one of the following: 1) onset of CMV end-organ disease, or 2) initiation of anti-CMV pre-emptive therapy based on documented CMV viremia and the clinical condition of the participant. The percentage of participants with clinically-significant CMV infection was assessed.

    Time frame: Up to Week 14 post-transplant

  3. Percentage of Participants With CMV End-organ Disease up to Week 24 Post-transplant

    CMV end-organ disease met per-protocol diagnostic criteria for CMV-pneumonia, gastrointestinal disease, hepatitis, central nervous system disease, retinitis, nephritis, cystitis, myocarditis, pancreatitis, or other disease categories. Only Clinical Adjudication Committee-confirmed CMV end-organ disease was included in this analysis. The percentage of participants with CMV end-organ disease was assessed.

    Time frame: Up to Week 24 post-transplant

  4. Percentage of Participants With CMV End-organ Disease up to Week 14 Post-transplant

    CMV end-organ disease met per-protocol diagnostic criteria for CMV-pneumonia, gastrointestinal disease, hepatitis, central nervous system disease, retinitis, nephritis, cystitis, myocarditis, pancreatitis, or other disease categories. Only Clinical Adjudication Committee-confirmed CMV end-organ disease was included in this analysis. The percentage of participants with CMV end-organ disease was assessed.

    Time frame: Up to Week 14 post-transplant

  5. Percentage of Participants With Pre-emptive Therapy for CMV Viremia up to Week 14 Post-transplant

    Initiation of anti-CMV pre-emptive therapy was based on documented CMV viremia and the clinical condition of the participant. The percentage of participants with initiation of anti-CMV pre-emptive anti-CMV therapy was assessed.

    Time frame: Up to Week 14 post-transplant

  6. Percentage of Participants With Pre-emptive Therapy for CMV Viremia up to Week 24 Post-transplant

    Initiation of anti-CMV pre-emptive therapy was based on documented CMV viremia and the clinical condition of the participant. The percentage of participants with initiation of anti-CMV pre-emptive anti-CMV therapy was assessed.

    Time frame: Up to Week 24 post-transplant

  7. Time to Initiation of Pre-emptive Therapy for CMV Viremia (Kaplan-Meier Estimate of Percentage of Participants With a Qualifying Event at Week 24 Post-transplant)

    The need for anti-CMV pre-emptive therapy was based on documented CMV viremia and the clinical condition of the participant. The outcome was calculated from the day of transplantation to the start of anti-CMV pre-emptive therapy, and was analyzed by the Kaplan-Meier method. Participants were censored at the last assessment for participants who discontinued or did not initiate pre-emptive therapy.

    Time frame: Up to Week 24 post-transplant

Other outcomes

  1. Percentage of Participants With One or More Adverse Events up to Week 48 Post-transplant

    An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event.

    Time frame: Up to Week 48 post-transplant

  2. Percentage of Participants Discontinued From Study Medication Due to an Adverse Event

    An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event.

    Time frame: Up to Week 14 post-transplant

07

Results

Posted Nov 17, 2017

Participant flow

A total of 738 participants were screened, 570 were randomized 2:1 letermovir:placebo, and 565 received at least one dose of study medication.

Participant flow — Overall Study
MilestoneLetermovirPlacebo
Started376194
Treated participants373192
Completed244119
Not completed13275
Withdrew: Adverse event63
Withdrew: Death7144
Withdrew: Lost to follow-up84
Withdrew: Physician decision155
Withdrew: Withdrawal by subject2817
Withdrew: Non-compliance with study drug10
Withdrew: Not treated32

Outcome measures

PrimaryPercentage of Participants With Clinically-significant CMV Infection up to Week 24 Post-transplant

Clinically-significant CMV infection was defined as either one of the following: 1) onset of CMV end-organ disease, or 2) initiation of anti-CMV pre-emptive therapy based on documented CMV viremia and the clinical condition of the participant. The percentage of participants with clinically-significant CMV infection was assessed.

Time frame:
Up to Week 24 post-transplant
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinically-significant CMV Infection up to Week 24 Post-transplant
Percentage of participantsLetermovirPlacebo
Percentage of Participants With Clinically-significant CMV Infection up to Week 24 Post-transplant37.560.6
Statistical analysis
  • Letermovir vs Placebo · Mantel Haenszel · p = <0.0001 (A 1-sided p-value ≤0.0249 for the risk difference was used for declaring statistical significance) · Risk difference (rd): -23.5 · 95% CI -32.5 to -14.6The Mantel Haenszel analysis was adjusted for sample size for each stratum (high or low risk for CMV reactivation)
SecondaryTime to Onset of Clinically-significant CMV Infection (Kaplan-Meier Estimate of Percentage of Participants With a Qualifying Event at Week 24 Post-transplant)

Clinically-significant CMV infection was defined as either one of the following: 1) onset of CMV end-organ disease, or 2) initiation of anti-CMV pre-emptive therapy based on documented CMV viremia and the clinical condition of the participant. Time to onset of clinically-significant CMV infection was defined from the day of transplantation to the day the participant developed clinically-significant CMV infection, and was analyzed by the Kaplan-Meier method. Participants were censored at the last assessment for participants who discontinued or did not develop clinically-significant CMV infection.

Time frame:
Up to Week 24 post-transplant
Reported as:
Number · Percentage of participants
Time to Onset of Clinically-significant CMV Infection (Kaplan-Meier Estimate of Percentage of Participants With a Qualifying Event at Week 24 Post-transplant)
Percentage of participantsLetermovirPlacebo
Time to Onset of Clinically-significant CMV Infection (Kaplan-Meier Estimate of Percentage of Participants With a Qualifying Event at Week 24 Post-transplant)18.9 (14.4 to 23.5)44.3 (36.4 to 52.1)
Statistical analysis
  • Letermovir vs Placebo · Log Rank · p = <0.0001 (Nominal 2-sided p-value)The log rank test was adjusted for sample size for each stratum (high or low risk for CMV reactivation)
SecondaryPercentage of Participants With Clinically-significant CMV Infection up to Week 14 Post-transplant

Clinically-significant CMV infection was defined as either one of the following: 1) onset of CMV end-organ disease, or 2) initiation of anti-CMV pre-emptive therapy based on documented CMV viremia and the clinical condition of the participant. The percentage of participants with clinically-significant CMV infection was assessed.

Time frame:
Up to Week 14 post-transplant
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinically-significant CMV Infection up to Week 14 Post-transplant
Percentage of participantsLetermovirPlacebo
Percentage of Participants With Clinically-significant CMV Infection up to Week 14 Post-transplant19.150.0
Statistical analysis
  • Letermovir vs Placebo · Mantel Haenszel · p = <0.0001 (Nominal 1-sided p-value) · Risk difference (rd): -31.3 · 95% CI -39.9 to -22.6The Mantel Haenszel analysis was adjusted for sample size for each stratum (high or low risk for CMV reactivation)
SecondaryPercentage of Participants With CMV End-organ Disease up to Week 24 Post-transplant

CMV end-organ disease met per-protocol diagnostic criteria for CMV-pneumonia, gastrointestinal disease, hepatitis, central nervous system disease, retinitis, nephritis, cystitis, myocarditis, pancreatitis, or other disease categories. Only Clinical Adjudication Committee-confirmed CMV end-organ disease was included in this analysis. The percentage of participants with CMV end-organ disease was assessed.

Time frame:
Up to Week 24 post-transplant
Reported as:
Number · Percentage of participants
Percentage of Participants With CMV End-organ Disease up to Week 24 Post-transplant
Percentage of participantsLetermovirPlacebo
Percentage of Participants With CMV End-organ Disease up to Week 24 Post-transplant2.02.4
Statistical analysis
  • Letermovir vs Placebo · Mantel Haenszel · p = 0.4056 (Nominal 1-sided p-value) · Risk difference (rd): -0.4 · 95% CI -4.0 to 3.2The Mantel Haenszel analysis was adjusted for sample size for each stratum (high or low risk for CMV reactivation)
SecondaryPercentage of Participants With CMV End-organ Disease up to Week 14 Post-transplant

CMV end-organ disease met per-protocol diagnostic criteria for CMV-pneumonia, gastrointestinal disease, hepatitis, central nervous system disease, retinitis, nephritis, cystitis, myocarditis, pancreatitis, or other disease categories. Only Clinical Adjudication Committee-confirmed CMV end-organ disease was included in this analysis. The percentage of participants with CMV end-organ disease was assessed.

Time frame:
Up to Week 14 post-transplant
Reported as:
Number · Percentage of participants
Percentage of Participants With CMV End-organ Disease up to Week 14 Post-transplant
Percentage of participantsLetermovirPlacebo
Percentage of Participants With CMV End-organ Disease up to Week 14 Post-transplant0.41.4
Statistical analysis
  • Letermovir vs Placebo · Mantel Haenszel · p = 0.2258 (Nominal 1-sided p-value) · Risk difference (rd): -1.0 · 95% CI -3.5 to 1.5The Mantel Haenszel analysis was adjusted for sample size for each stratum (high or low risk for CMV reactivation)
SecondaryPercentage of Participants With Pre-emptive Therapy for CMV Viremia up to Week 14 Post-transplant

Initiation of anti-CMV pre-emptive therapy was based on documented CMV viremia and the clinical condition of the participant. The percentage of participants with initiation of anti-CMV pre-emptive anti-CMV therapy was assessed.

Time frame:
Up to Week 14 post-transplant
Reported as:
Number · Percentage of participants
Percentage of Participants With Pre-emptive Therapy for CMV Viremia up to Week 14 Post-transplant
Percentage of participantsLetermovirPlacebo
Percentage of Participants With Pre-emptive Therapy for CMV Viremia up to Week 14 Post-transplant18.849.4
Statistical analysis
  • Letermovir vs Placebo · Mantel Haenszel · p = <0.0001 (Nominal 1-sided p-value) · Risk difference (rd): -31.0 · 95% CI -39.6 to -22.4The Mantel Haenszel analysis was adjusted for sample size for each stratum (high or low risk for CMV reactivation)
SecondaryPercentage of Participants With Pre-emptive Therapy for CMV Viremia up to Week 24 Post-transplant

Initiation of anti-CMV pre-emptive therapy was based on documented CMV viremia and the clinical condition of the participant. The percentage of participants with initiation of anti-CMV pre-emptive anti-CMV therapy was assessed.

Time frame:
Up to Week 24 post-transplant
Reported as:
Number · Percentage of participants
Percentage of Participants With Pre-emptive Therapy for CMV Viremia up to Week 24 Post-transplant
Percentage of participantsLetermovirPlacebo
Percentage of Participants With Pre-emptive Therapy for CMV Viremia up to Week 24 Post-transplant36.659.4
Statistical analysis
  • Letermovir vs Placebo · Mantel Haenszel · p = <0.0001 (Nominal 1-sided p-value) · Risk difference (rd): -23.3 · 95% CI -32.3 to -14.3The Mantel Haenszel analysis was adjusted for sample size for each stratum (high or low risk for CMV reactivation)
SecondaryTime to Initiation of Pre-emptive Therapy for CMV Viremia (Kaplan-Meier Estimate of Percentage of Participants With a Qualifying Event at Week 24 Post-transplant)

The need for anti-CMV pre-emptive therapy was based on documented CMV viremia and the clinical condition of the participant. The outcome was calculated from the day of transplantation to the start of anti-CMV pre-emptive therapy, and was analyzed by the Kaplan-Meier method. Participants were censored at the last assessment for participants who discontinued or did not initiate pre-emptive therapy.

Time frame:
Up to Week 24 post-transplant
Reported as:
Number · Percentage of participants
Time to Initiation of Pre-emptive Therapy for CMV Viremia (Kaplan-Meier Estimate of Percentage of Participants With a Qualifying Event at Week 24 Post-transplant)
Percentage of participantsLetermovirPlacebo
Time to Initiation of Pre-emptive Therapy for CMV Viremia (Kaplan-Meier Estimate of Percentage of Participants With a Qualifying Event at Week 24 Post-transplant)17.2 (12.8 to 21.6)42.4 (34.7 to 50.2)
Statistical analysis
  • Letermovir vs Placebo · Log Rank · p = <0.0001 (Nominal 2-sided p-value)The log rank test analysis was adjusted for sample size for each stratum (high or low risk for CMV reactivation)
Other pre-specifiedPercentage of Participants With One or More Adverse Events up to Week 48 Post-transplant

An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event.

Time frame:
Up to Week 48 post-transplant
Reported as:
Number · Percentage of participants
Percentage of Participants With One or More Adverse Events up to Week 48 Post-transplant
Percentage of participantsLetermovirPlacebo
Percentage of Participants With One or More Adverse Events up to Week 48 Post-transplant98.4100.0
Other pre-specifiedPercentage of Participants Discontinued From Study Medication Due to an Adverse Event

An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event.

Time frame:
Up to Week 14 post-transplant
Reported as:
Number · Percentage of participants
Percentage of Participants Discontinued From Study Medication Due to an Adverse Event
Percentage of participantsLetermovirPlacebo
Percentage of Participants Discontinued From Study Medication Due to an Adverse Event19.651.6

Adverse events

Collected over Up to Week 48 post-transplant. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Letermovir—202/373 (54.2%)360/373 (96.5%)
Placebo—115/192 (59.9%)186/192 (96.9%)
Most frequent serious events
Showing 10 of 230
Most frequent serious events
EventLetermovirPlacebo
Graft versus host diseaseImmune system disorders45/37329/192
Acute myeloid leukaemia recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps)23/37317/192
Cytomegalovirus infectionInfections and infestations14/37315/192
Acute kidney injuryRenal and urinary disorders7/3739/192
PneumoniaInfections and infestations15/3736/192
Septic shockInfections and infestations5/3737/192
PyrexiaGeneral disorders10/3734/192
DiarrhoeaGastrointestinal disorders3/3735/192
SepsisInfections and infestations8/3734/192
Multiple organ dysfunction syndromeGeneral disorders2/3734/192
Most frequent other events
Showing 10 of 59
Most frequent other events
EventLetermovirPlacebo
Cytomegalovirus infectionInfections and infestations55/37377/192
Graft versus host diseaseImmune system disorders147/37374/192
DiarrhoeaGastrointestinal disorders108/37351/192
NauseaGastrointestinal disorders106/37353/192
RashSkin and subcutaneous tissue disorders90/37351/192
PyrexiaGeneral disorders85/37350/192
VomitingGastrointestinal disorders79/37335/192
CoughRespiratory, thoracic and mediastinal disorders62/37327/192
Oedema peripheralGeneral disorders60/37323/192
HeadacheNervous system disorders58/37324/192

Baseline characteristics

Randomized participants

Age, Continuous
Age, Continuous(Years)LetermovirPlaceboTotal
Mean50.8 ± 13.450.8 ± 14.850.8 ± 13.9
Sex: Female, Male
Sex: Female, Male(Participants)LetermovirPlaceboTotal
Female16277239
Male214117331
Risk Stratum for CMV Reactivation
Risk Stratum for CMV Reactivation(Participants)LetermovirPlaceboTotal
High risk12254176
Low risk254140394
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Prohn M, Cho CR, Viberg A, Dykstra K, Davis C, Sabato P, Stone J, Badshah C, Murata Y, Leavitt R, Fancourt C, Macha S. Exposure-Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation Recipients. Clin Pharmacol Ther. 2022 Feb;111(2):485-495. doi: 10.1002/cpt.2456. Epub 2021 Nov 29. PubMed 34674258 ↗
  • Prohn M, Viberg A, Zhang D, Dykstra K, Davis C, Macha S, Sabato P, de Alwis D, Iwamoto M, Fancourt C, Cho CR. Population pharmacokinetics of letermovir following oral and intravenous administration in healthy participants and allogeneic hematopoietic cell transplantation recipients. CPT Pharmacometrics Syst Pharmacol. 2021 Mar;10(3):255-267. doi: 10.1002/psp4.12593. Epub 2021 Mar 12. PubMed 33440077 ↗
  • Ljungman P, Schmitt M, Marty FM, Maertens J, Chemaly RF, Kartsonis NA, Butterton JR, Wan H, Teal VL, Sarratt K, Murata Y, Leavitt RY, Badshah C. A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation. Clin Infect Dis. 2020 Apr 10;70(8):1525-1533. doi: 10.1093/cid/ciz490. PubMed 31179485 ↗
  • Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, Haider S, Ullmann AJ, Katayama Y, Brown J, Mullane KM, Boeckh M, Blumberg EA, Einsele H, Snydman DR, Kanda Y, DiNubile MJ, Teal VL, Wan H, Murata Y, Kartsonis NA, Leavitt RY, Badshah C. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N Engl J Med. 2017 Dec 21;377(25):2433-2444. doi: 10.1056/NEJMoa1706640. Epub 2017 Dec 6. PubMed 29211658 ↗

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2014 to primary completion in Aug 2016, 26 months.

Results were first posted in Nov 2017, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2014
First posted
May 14, 2014
StartActual
Jun 6, 2014
Primary completionActual
Aug 8, 2016
CompletionActual
Nov 21, 2016
Results first posted
Nov 17, 2017
Last update
Sep 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02137772
Responsible party
Sponsor
First posted
May 14, 2014
Start date
Jun 6, 2014
Primary completion
Aug 8, 2016
Completion
Nov 21, 2016
Results posted
Nov 17, 2017
Last update
Sep 11, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letermovir

Start the discussion